CD56 negative NKTCL differs from CD56 positive NKTCL in both the tumor microenvironment and survival outcomes, and asparaginase-based treatment may overcome the poor prognosis brought by CD56 negativity. Here, NCAM1 is linked to extranodal nasal NK/T cell lymphoma.